SCHEMBL1825548

SCHEMBL1825548

CCC(=O)Nc1ccc(OCc2ccc(Cl)cc2Br)cc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
GAA P10253 1/20 0.47
HSD17B10 Q99714 1/20 0.45
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
PKM P14618 1/20 0.44
NR4A2 P43354 1/20 0.44
SERPINE1 P05121 2/20 0.43
POLB P06746 1/20 0.43
G6PD P11413 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1823550 0.89 MEN1 (0.54) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1825956 0.89 NR4A2 (0.57) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1824136 0.87 MEN1 (0.44) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1826022 0.87 KDM4E (0.54) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4437748 0.85 MEN1 (0.40) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1823212 0.85 KDM4E (0.52) KDM4EKMT2AALDH1A1HSD17B10NR4A2
SCHEMBL1826502 0.85 MEN1 (0.52) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1827458 0.84 KDM4E (0.51) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1824443 0.84 FFAR1 (0.43) KDM4EMEN1KMT2AALDH1A1PKM
SCHEMBL4437310 0.82 KDM4E (0.48) KDM4EMEN1KMT2AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461205-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2013-06-11 US claimed
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES CHELSEA THERAPEUTICS, INC. 2012-11-08 US claimed
US-8263658-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2012-09-11 US claimed
EP-2118051-B1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF CHELSEA THERAPEUTICS INC (US) 2011-05-04 EP claimed
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES Chelsea Therapeutics, Inc 2010-02-04 US claimed
US-8461205-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2013-06-11 US disclosed
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES CHELSEA THERAPEUTICS, INC. 2012-11-08 US disclosed
US-8263658-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2012-09-11 US disclosed
EP-2118051-B1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF CHELSEA THERAPEUTICS INC (US) 2011-05-04 EP disclosed
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES Chelsea Therapeutics, Inc 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES ACOX3, BCL3, AOC3 KDM4E 4207/4885MEN1 1718/4885KMT2A 3537/4885
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES ACOX3, BCL3, AOC3 KDM4E 4172/4885MEN1 1752/4885KMT2A 3535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.